Several circulating proteins and RNA molecules have been proposed as diagnostic and prognostic biomarkers of MPM (5–9) but only the glycoprotein mesothelin has been approved by the US Food and Drug Administration as a biomarker used to determine tumor response to treatment (10). The gene discussed is MSLN; the disease is neoplasm.